Biotech — September 2026

Montana lets firms sell unapproved drugs to patients

A private board with industry ties decides who can sell experimental medicine there.

Definium's LSD pill clears third straight Phase 3 trial

DT120, a dissolvable LSD tablet for anxiety, hit its main goal in a third Phase 3 trial, and the company is heading toward an FDA filing.

Diabetes Care editors boycott the ADA after police ouster

Police escorted five researchers out in June for handing out an editorial on research cuts. Now their journal's editors refuse to review new papers.

A gene therapy just reversed aging signs in senior dogs

Genflow's SIRT6 gene therapy hit its main goal in aged beagles, lowering their biological age and improving survival.

Kura spins off $50M diabetes biotech with Lilly's backing

The new company, Caspian Therapeutics, is chasing a treatment that could change how diabetes progresses, not just manage blood sugar.

Moonwalk raises $70M for a muscle-sparing fat drug

The Bay Area biotech's new injection aims to cut fat while keeping muscle, unlike today's popular GLP-1 weight-loss drugs.

A new cancer pill won FDA approval. Patients can't get it

Rasonque treats a genetic driver of pancreatic cancer, but insurance delays are leaving newly-approved patients stuck for weeks, STAT found.

Novo Nordisk halts two heart trials of ziltivekimab

A data-monitoring committee found the trials unlikely to succeed, another blow to the inflammation theory of heart disease.

Novartis' new heart drug fails its big trial

Pelacarsen lowered a key heart-disease marker, but that didn't mean fewer heart attacks or strokes in a big trial.

FDA approves first-ever drug for Alexander disease

Zanvastro is the first treatment that changes the course of Alexander disease, a rare brain disorder in kids and adults.

Akeso's drug beats Keytruda in a head-to-head trial

Ivonescimab outlived Merck's blockbuster in a Phase 3 lung cancer study, the first rival drug to do it.

Ultragenyx's Angelman syndrome drug fails Phase 3 trial

Ultragenyx's experimental drug for the rare disorder Angelman syndrome missed its main goals in a major trial, and shares dropped over 40%.

GSK moves its mRNA flu vaccine into Phase 3 trials

Early data show GSK's shot beats standard flu vaccines at triggering immune responses, in both younger and older adults.

Novartis halts CAR-T trials after three deaths

Three patients died from severe immune reactions in Novartis trials, prompting Bristol Myers to pause similar studies too.